Metcela is a clinical-stage biotechnology company focused on developing innovative cell therapies to address chronic organ diseases, particularly heart conditions. Their flagship product, JRM-001, is an autologous cell therapy utilizing cardiac stem cells (CSCs) derived from the patient's own heart. This therapy aims to treat single ventricle conditions, which are congenital heart defects that severely impair blood circulation. The technology behind JRM-001 is based on a patented CSC-based pipeline developed in collaboration with Okayama University, where initial clinical studies have demonstrated its safety and efficacy in pediatric patients. Metcela has also secured exclusive licensing and technical guidance from Okayama University to further advance this promising treatment.

In addition to JRM-001, Metcela is developing MTC001, another autologous cell therapy designed for adult heart failure. This therapy combines specialized cardiac fibroblasts with a minimally invasive catheter delivery system, allowing for safer and more efficient administration compared to traditional surgical methods. The company is also collaborating with Nagoya University to explore the therapeutic potential of fibroblasts in treating cardiovascular and respiratory diseases. This partnership aims to enhance research capabilities and accelerate the development of new treatment pipelines, ultimately contributing to improved patient outcomes in chronic organ diseases.

Japan

Revolutionizing the Way We Treat Heart Failure

Heart failure kills more people globally than any other ailments, yet there is no ultimate treatment for the condition. Our goal is to develop and commercialize an effective and reasonably-priced therapy for heart failure using a specific fibroblast cells we call “VCF”, that we obtain from the patient’s own heart.

Our approach to heart failure therapy is quite different from other technologies in a sense that we do not want to replace what is “broken”, but rather we want to repair the damage by enhancing the cells’ own ability to heal.

Metcela

Company Details